DE69930740T2 - Thienyl substituierte acylguanidine als knochenresorptionshemmer und als vitronectin-rezeptor antagonisten - Google Patents

Thienyl substituierte acylguanidine als knochenresorptionshemmer und als vitronectin-rezeptor antagonisten Download PDF

Info

Publication number
DE69930740T2
DE69930740T2 DE69930740T DE69930740T DE69930740T2 DE 69930740 T2 DE69930740 T2 DE 69930740T2 DE 69930740 T DE69930740 T DE 69930740T DE 69930740 T DE69930740 T DE 69930740T DE 69930740 T2 DE69930740 T2 DE 69930740T2
Authority
DE
Germany
Prior art keywords
alkyl
aryl
cycloalkyl
hydrogen
radicals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69930740T
Other languages
German (de)
English (en)
Other versions
DE69930740D1 (en
Inventor
Karl-Heinz Scheunemann
Jochen Knolle
Anuschirwan Peyman
William David WILL
Denis Carniato
Jean-Francois Gourvest
Thomas Oakland GADEK
Robert San Francisco MCDOWELL
Catherine Sarah San Bruno BODARY
Andrew Robert North Fitzroy CUTHBERTSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Genentech Inc
Original Assignee
Sanofi Aventis Deutschland GmbH
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH, Genentech Inc filed Critical Sanofi Aventis Deutschland GmbH
Application granted granted Critical
Publication of DE69930740D1 publication Critical patent/DE69930740D1/de
Publication of DE69930740T2 publication Critical patent/DE69930740T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69930740T 1998-05-19 1999-05-05 Thienyl substituierte acylguanidine als knochenresorptionshemmer und als vitronectin-rezeptor antagonisten Expired - Lifetime DE69930740T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98109077 1998-05-19
EP98109077A EP0960882A1 (en) 1998-05-19 1998-05-19 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
PCT/EP1999/003064 WO1999059992A1 (en) 1998-05-19 1999-05-05 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
DE69930740D1 DE69930740D1 (en) 2006-05-18
DE69930740T2 true DE69930740T2 (de) 2007-04-12

Family

ID=8231959

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930740T Expired - Lifetime DE69930740T2 (de) 1998-05-19 1999-05-05 Thienyl substituierte acylguanidine als knochenresorptionshemmer und als vitronectin-rezeptor antagonisten

Country Status (9)

Country Link
US (2) US6566366B1 (enExample)
EP (2) EP0960882A1 (enExample)
JP (1) JP4503176B2 (enExample)
AR (1) AR018358A1 (enExample)
AT (1) ATE322490T1 (enExample)
AU (1) AU4138599A (enExample)
DE (1) DE69930740T2 (enExample)
TW (2) TW546294B (enExample)
WO (1) WO1999059992A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6965165B2 (en) 1998-12-21 2005-11-15 Mou-Shiung Lin Top layers of metal for high performance IC's
US7381642B2 (en) 2004-09-23 2008-06-03 Megica Corporation Top layers of metal for integrated circuits
US7405149B1 (en) 1998-12-21 2008-07-29 Megica Corporation Post passivation method for semiconductor chip or wafer
WO2000075129A1 (en) * 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
EP1108721A1 (en) 1999-12-15 2001-06-20 Aventis Pharma Deutschland GmbH Thienylalanine derivatives as inhibitors of cell adhesion
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE10041428A1 (de) * 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
EP2363396A1 (en) * 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
DE60332482D1 (de) 2002-12-10 2010-06-17 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
US7098241B2 (en) * 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP5030947B2 (ja) * 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
SG176488A1 (en) * 2006-11-15 2011-12-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
EP3118196A4 (en) * 2014-03-11 2018-02-21 EA Pharma Co., Ltd. Method for producing heteroarylcarboxylic acid ester derivative, and production intermediate of same
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
HUE057569T2 (hu) 2014-12-17 2022-05-28 Pimco 2664 Ltd N-(4-hidroxi-4-metil-ciklohexil)-4-fenil-benzolszulfonamid és N-(4-hidroxi-4-metil-ciklohexil)-4-(2-piridil)-benzolszulfonamid vegyületek és terápiás alkalmazásuk
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5125050A (en) * 1991-05-03 1992-06-23 Bell Communications Research, Inc. Vertical metallically loaded polarization splitter and polarization-diversified optical receiver
US5204350A (en) * 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
EP0667773A4 (en) * 1992-10-14 1996-09-25 Merck & Co Inc FIBRINOGEN RECEPTOR ANTAGONISTS.
ATE227567T1 (de) * 1994-05-27 2002-11-15 Merck & Co Inc Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
FR2742752B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveaux composes du thiophene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten

Also Published As

Publication number Publication date
TWI254710B (en) 2006-05-11
EP1086098A1 (en) 2001-03-28
WO1999059992A1 (en) 1999-11-25
JP4503176B2 (ja) 2010-07-14
JP2002515500A (ja) 2002-05-28
TW546294B (en) 2003-08-11
EP0960882A1 (en) 1999-12-01
EP1086098B1 (en) 2006-04-05
AR018358A1 (es) 2001-11-14
US6566366B1 (en) 2003-05-20
DE69930740D1 (en) 2006-05-18
US6660728B2 (en) 2003-12-09
AU4138599A (en) 1999-12-06
US20030153557A1 (en) 2003-08-14
ATE322490T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
DE69809594T2 (de) Acylguanidin derivate als inhibitoren von knochenresorption und als vitronectin rezeptor antagonisten
EP1086098B1 (en) Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
DE60022890T4 (de) Naphthyridine derivate, verfahren zu ihrer herstellung, deren anwendung und sie enthaltende pharmazeutische zusammensetzungen
JP2002501054A (ja) 骨吸収の阻害剤として及び細胞接着の阻害剤としての新規のスルホンアミド誘導体
DE60012890T2 (de) Neue guanidin-derivate als zelladhäsion-inhibitoren
DE60009296T2 (de) Substituierte purine-derivate als zell-adhäsionhemmer
JP4550286B2 (ja) 新規なアシルグアニジン誘導体、それらの製造方法、薬剤としてのそれらの使用及びそれらを含有する製薬組成物
DE60034482T2 (de) Thienylalaninderivate als inhibitoren der zelladhäsion
JP4522586B2 (ja) 新規のベンゾフラン誘導体、それらの製造方法及び薬剤としてのそれらの使用
MXPA00006068A (en) Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: CABINET HIRSCH, 80807 MUENCHEN